Chromatin Accessibility

Chromatin accessibility describes the openness or compaction state of DNA within nucleosomes and higher-order chromatin structures, fundamentally governing gene transcription, replication, and repair. Open chromatin regions permit transcription factor binding and RNA polymerase recruitment, whereas condensed heterochromatin restricts access and silences gene expression. Epigenetic modifications including histone acetylation, DNA methylation patterns, and chromatin remodelling complex activity regulate accessibility dynamically. Assay techniques including ATAC-seq, DNase-seq, and ChIP-seq map accessible regions genome-wide, informing therapeutic target identification and mechanism-of-action studies.

Therapeutic manipulation of chromatin accessibility represents an emerging modality targeting epigenetic dysfunction in cancer, neurological disease, and rare genetic disorders. Histone deacetylase inhibitors increase acetylation promoting accessible chromatin states and reactivating silenced tumour suppressors. DNA methyltransferase inhibitors reverse aberrant methylation patterns restoring normal gene expression. Bromodomain and extra-terminal domain inhibitors disrupt protein-protein interactions required for chromatin remodelling. As understanding of epigenetic dysregulation advances, chromatin-targeting therapeutics increasingly demonstrate clinical efficacy particularly in haematologic malignancies and are expanding into solid tumours.